SCHEMBL2483573

SCHEMBL2483573

COC(=O)C(CCCCN1C(=O)c2ccccc2C1=O)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.52
HDAC7 Q8WUI4 6/20 0.52
ALDH1A1 P00352 4/20 0.51
HDAC8 Q9BY41 3/20 0.49
HDAC3 O15379 2/20 0.49
HDAC4 P56524 2/20 0.49
HDAC2 Q92769 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
HDAC9 Q9UKV0 2/20 0.49
HDAC5 Q9UQL6 2/20 0.49
NPC1 O15118 1/20 0.48
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HTT P42858 1/20 0.46
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30278697 0.86 ALDH1A1 (0.48) ALDH1A1HSD17B10HPGDHTTKDM4E
SCHEMBL11773628 0.86 ALDH1A1 (0.55) ALDH1A1HSD17B10HPGDHTTKDM4E
SCHEMBL29256396 0.85 ASAH1 (0.49) ALDH1A1HSD17B10HPGDHTTKDM4E
SCHEMBL8446739 0.84 TP53 (0.51) ALDH1A1HSD17B10HPGDHTTKDM4E
SCHEMBL24130616 0.83 ALDH1A1 (0.64) HDAC1HDAC7ALDH1A1HDAC8HDAC3
SCHEMBL7370340 0.83 HSD17B10 (0.51) HDAC1HDAC7ALDH1A1HDAC8HDAC3
SCHEMBL21851961 0.83 ALDH1A1 (0.64) HDAC1HDAC7ALDH1A1HDAC8HDAC3
SCHEMBL30299434 0.83 ALDH1A1 (0.64) HDAC1HDAC7ALDH1A1HDAC8HDAC3
Hydrochloric Acid SCHEMBL4804796 0.83 TP53 (0.50) ALDH1A1HSD17B10HPGDHTTKDM4E
SCHEMBL29166106 0.83 HDAC7 (0.53) HDAC1HDAC7ALDH1A1HDAC8HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1017358-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-08-11 EP claimed
EP-1017358-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-07-12 EP claimed
US-5939458-A APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN GILLETTE COMPANY, THE 1999-08-17 US claimed
WO-1999015136-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-04-01 WO claimed
EP-3212183-B1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIV ROCHESTER (US) 2019-10-02 EP disclosed
US-10028931-B2 Synergistic compositions for treating microbial infections UNIVERSITY OF ROCHESTER (US) 2018-07-24 US disclosed
EP-3212183-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS University of Rochester (US) 2017-09-06 EP disclosed
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2017-08-31 US disclosed
WO-2016070021-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2016-05-06 WO disclosed
CN-102348807-B Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system SUTRO BIOPHARMA INC 2015-04-15 CN disclosed
US-8778631-B2 Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system SUTRO BIOPHARMA, INC. (US) 2014-07-15 US disclosed
EP-2376647-B1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA INC (US) 2014-03-05 EP disclosed
US-20100184134-A1 DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD SUTRO BIOPHARMA, INC. (US) 2010-07-22 US disclosed
US-20100184135-A1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA, INC. (US) 2010-07-22 US disclosed
WO-2010081110-A1 DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD SUTRO BIOPHARMA, INC. (US) 2010-07-15 WO disclosed
WO-2010081111-A1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA, INC. (US) 2010-07-15 WO disclosed
EP-1017358-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-08-11 EP disclosed
EP-1017358-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-07-12 EP disclosed
US-5939458-A APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN GILLETTE COMPANY, THE 1999-08-17 US disclosed
WO-1999015136-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028931-B2 Synergistic compositions for treating microbial infections RNASE1, RNASEL, RNASEH1 HDAC1 1400/4885HDAC7 771/4885ALDH1A1 3822/4885
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS RNASE1, RNASEL, RNASEH1 HDAC1 1400/4885HDAC7 771/4885ALDH1A1 3822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.